Pimavanserin for the Treatment of Irritability Associated With ASD

Pimavanserin for the Treatment of Irritability Associated With ASD

Contact

 If you are interested in participating in the study or want to learn more, please get in touch. Contact us
This study is no longer recruiting.

Description

The purpose of this study is to test an investigational medication in children and adolescents aged 5-17 years old with irritability associated with autism spectrum disorder (ASD). The name of the medication being tested in this study is pimavanserin. This medication is investigational because it has not been approved by the FDA for the treatment of irritability associated with autism. The main risks of this study are from the medication, which include nausea, dizziness, and sleepiness.


Eligibility and criteria
IRB Number:
22-019780
Eligible age range:
5 years - 17 years
Clinical trial phase:
Phase II
Official title:
A Phase 2, Randomized, Double-blind, Placebo- Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder

What to expect


Related specialties
Smiling CHOP patient holding shopping bag

We need families like you

Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.